Avalo-Final_Black-01.jpg
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
September 17, 2021 09:11 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo-Final_Black-01.jpg
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
September 14, 2021 22:23 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo-Final_Black-01.jpg
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
September 14, 2021 16:01 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
cerecor-logo-final.png
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
August 26, 2021 07:30 ET | Cerecor Inc.
Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates...
cerecor-logo-final.png
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 02, 2021 16:01 ET | Cerecor Inc.
Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including...
cerecor-logo-final.png
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
August 02, 2021 07:30 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
cerecor-logo-final.png
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
July 26, 2021 16:01 ET | Cerecor Inc.
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF...
cerecor-logo-final.png
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
June 23, 2021 07:30 ET | Cerecor Inc.
ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
cerecor-logo-final.png
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
June 07, 2021 07:00 ET | Cerecor Inc.
An initial tranche of $20 million drawn at the loan closingFunds ongoing clinical development of key investigational product candidatesFinancing provides flexibility and extends runway through...